SCHEMBL3485635

SCHEMBL3485635

COc1ccc2c(c1)/C(=C/c1cc3ccccc3[nH]1)C(=O)N2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLK2 Q86UE8 5/20 0.64
▸ PDPK1 O15530 2/20 0.64
▸ RET P07949 6/20 0.58
▸ CDK2 P24941 3/20 0.58
▸ KDR P35968 3/20 0.58
▸ CDK1 P06493 2/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ GSK3A P49840 2/20 0.58
▸ GSK3B P49841 2/20 0.58
▸ CDK7 P50613 2/20 0.58
▸ CDK9 P50750 2/20 0.58
▸ CDK5 Q00535 2/20 0.58
▸ CCNE1 P24864 2/20 0.58
▸ LCK P06239 2/20 0.58
▸ NTRK1 P04629 2/20 0.58
▸ PLK4 O00444 1/20 0.58
▸ CHEK1 O14757 1/20 0.58
▸ AURKA O14965 1/20 0.58
▸ JAK2 O60674 1/20 0.58
▸ ROCK2 O75116 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768013 0.82 KDR (0.59) TLK2PDPK1RETCDK2KDR
SCHEMBL1538367 0.82 KDR (0.59) TLK2PDPK1RETCDK2KDR
SCHEMBL6389451 0.82 KDR (0.58) PDPK1RETCDK2KDRCDK1
SCHEMBL6389448 0.82 KDR (0.58) PDPK1RETCDK2KDRCDK1
SCHEMBL6390272 0.82 RET (0.62) PDPK1RETKDRFGFR1FLT3
SCHEMBL6390271 0.82 RET (0.62) PDPK1RETKDRFGFR1FLT3
SCHEMBL6389287 0.82 LRRK2 (0.62) RETRPS6KA3PDGFRBLRRK2SIRT1
SCHEMBL6389284 0.82 LRRK2 (0.62) RETRPS6KA3PDGFRBLRRK2SIRT1
SCHEMBL6393587 0.81 TLK2 (0.65) TLK2PDPK1KDRCDK1FGFR1
SCHEMBL6393582 0.81 TLK2 (0.65) TLK2PDPK1KDRCDK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035251-A1 BioMarkers for the Progression of Alzheimer's Disease HE YUNSHENG 2010-02-11 — — US disclosed
EP-2035582-A2 BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE Novartis AG (CH) 2009-03-18 — — EP disclosed
WO-2007149798-A2 BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE NOVARTIS AG (CH) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035251-A1 BioMarkers for the Progression of Alzheimer's Disease LRRK2, PSEN2, CLK2 TLK2 9/4885PDPK1 165/4885RET 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback